Boehringer Ingelheim's new obesity therapy, survodutide, has demonstrated significant results in a Phase 3 trial, with patients achieving an average weight loss of up to 16.6% over 76 weeks. The drug targets both appetite reduction and liver metabolism, aiming for a differentiated approach in the competitive weight-loss market.
In the SYNCHRONIZE-1 trial, 85.1% of adult participants achieved at least a 5% weight loss, compared to 38.8% in the placebo group. Participants lost an average of 17.8 kg, with notable reductions in waist circumference. Early analysis indicates weight loss was primarily driven by fat mass reduction, minimizing lean tissue loss.
Survodutide is a dual agonist that reduces appetite and targets liver metabolism, potentially improving inflammation and fibrosis. While gastrointestinal events were observed, consistent with other GLP-1 based therapies, they were more frequent during dose escalation.
Professor Carel le Roux highlighted the urgent need for therapies that improve metabolic health beyond just weight reduction, stating survodutide's dual agonism addresses this significant unmet need. Boehringer Ingelheim will continue evaluating survodutide in further Phase 3 trials, including studies in patients with type 2 diabetes and metabolic dysfunction-associated steatohepatitis. Full results are anticipated in June 2026.